Cherifi S, Jacobs F, Strale H, Struelens M, Byl B
Infectious Diseases Department, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Clin Microbiol Infect. 2007 Jun;13(6):592-8. doi: 10.1111/j.1469-0691.2007.01699.x.
The optimal management of bacteraemia related to the presence of totally implantable venous access devices (TIVADs) remains controversial, particularly in terms of whether to remove the infected catheter. The objective of this study was to determine the factors associated with success or failure of treatment of TIVAD-related bacteraemia in patients from whom the infected device was not removed. The outcome of 92 episodes of TIVAD-related bacteraemia and the factors predictive of an unfavourable outcome were evaluated retrospectively. In 32 (35%) episodes, the devices were removed immediately. In 60 episodes, patients were treated with antibiotics infused through the device; treatment was successful in 56% of these cases (66% for infections caused by coagulase-negative staphylococci). Only the presence of sepsis (OR 9.42, 95% CI 1.29-68.92, p 0.0271) and of local signs of infection (OR 9.61, 95% CI 1.98-46.49, p 0.0049) independently predicted the failure of catheter-retaining treatment. Finally, only one-third of the devices were retained. In conclusion, the large number of TIVADs that are removed because of infection justifies reconsidering the criteria for device removal. During catheter-retaining treatment, the presence of local signs of infection or reported sepsis were independent factors for reduced probability of retaining the device.
与完全植入式静脉通路装置(TIVADs)相关的菌血症的最佳管理仍存在争议,特别是在是否移除感染导管方面。本研究的目的是确定在未移除感染装置的患者中,与TIVAD相关菌血症治疗成功或失败相关的因素。回顾性评估了92例TIVAD相关菌血症的结局以及预测不良结局的因素。在32例(35%)病例中,装置立即被移除。在60例病例中,患者通过装置输注抗生素进行治疗;其中56%的病例治疗成功(凝固酶阴性葡萄球菌引起的感染为66%)。只有脓毒症的存在(比值比9.42,95%置信区间1.29 - 68.92,p = 0.0271)和局部感染体征的存在(比值比9.61,95%置信区间1.98 - 46.49,p = 0.0049)独立预测了保留导管治疗的失败。最后,只有三分之一的装置被保留。总之,因感染而移除的TIVAD数量众多,这证明有必要重新考虑装置移除的标准。在保留导管治疗期间,局部感染体征或报告的脓毒症的存在是降低保留装置可能性的独立因素。